News Center

Home page

Peak Report

News reports

Shanghai North Carolina's wholly-owned acquisition of Anhui Zhongwang Jianfeng Pharmaceutical API Base is beginning to take shape.

Release time:

2020-07-31

News from our newspaper 8# April 3 , Shanghai Beika Pharmaceutical Technology Co., Ltd., a subsidiary of Jianfeng Pharmaceutical Co., Ltd., signed an equity transfer agreement with shareholders of Anhui Zhongwang Pharmaceutical Co., Ltd. to invest ,2062 yuan to acquire all 100% shares of the company. This is another important move to build a production base for API after the acquisition of equity in Shanghai North Carolina at the beginning of the year.

Anhui Zhongwang is located in Xiangyu Chemical Park, Dongzhi County, Chizhou City, Anhui Province. It is a pharmaceutical intermediate manufacturing enterprise integrating R & D, production and sales, focusing on characteristic medicine, intermediates, new materials, etc. R & D, production and sales of fine chemicals. The main business activities are the production and sales of 92% potassium hydrogen fluoride and 8% potassium fluoride mixture, ethyl acetate, aqueous DMF , aqueous triethylamine, toluene, methanol, acetic acid, DMF , triethylamine, industrial sodium chloride, chemical products (except hazardous chemicals and explosives); Research and development of biopharmaceuticals, chemical raw materials, pharmaceutical intermediates and fine chemicals. The company has two ofloxacin carboxylic acid production lines with a total production capacity of 1200 tons / years, and its supporting safety, environmental protection, storage and management systems, and has passed ISO9001 : 2015 quality management system certification, ISO14001 : 2015 environmental management system certification, OHSAS18001 : 2015 occupational health and safety management system certification and safety three-level standardization construction; the main products, oxyfluorocarboxylate, oxyfluorocarboxylate, levooxyfluorocarboxylate and levooxyfluorocarboxylate, passed the on-site audit of well-known domestic pharmaceutical enterprises, levofluorocarboxylate passed the on-site audit of Indian pharmaceutical enterprises, and received the on-site audit of oxyfluorocarboxylate process verification from U.S. pharmaceutical enterprises in 2017 , and was expected to be registered in U.S. document DMF as a supplier of oxyfluorocarboxylate starting materials. The equity acquisition of Anhui Zhongwang is an important measure to strengthen the development of the pharmaceutical business sector according to the company's strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development. After the acquisition, Anhui Zhongwang will become a wholly-owned subsidiary of Shanghai Beika. The company plans to use the factory building and construction land of Anhui Zhongwang to plan the construction of pharmaceutical intermediates and API projects, which is conducive to the overall layout of Jianfeng Pharmaceutical's chemical API base in Anhui: the pesticide and primary pharmaceutical intermediates will be arranged in the factory area of Anhui Xinbeika Chemical Co., Ltd., and the API and advanced pharmaceutical intermediates will be arranged in the factory area of Anhui Zhongwang, it can make full use of Anhui Zhongwang's factory area, public engineering facilities, quality management system and other advantages to speed up the construction progress of Jianfeng Pharmaceutical Anhui Chemical Raw Material Drug Base. In addition, the acquisition of Anhui Zhongwang will also help expand the R & D, production and sales of Shanghai North Carolina's existing fine chemicals business such as intermediates and new materials, further extend and improve the industrial chain, and consolidate its market position. (this newspaper reporter)

More information

2022 China's Top 100 Building Materials Enterprises 2022 China's Top 100 Cement Clinker Production Capacity Peak even on two authoritative lists

In March, the authoritative organization of the cement industry successively released two series of lists of China's top 500 building materials enterprises in 2022 and China's top 100 cement clinker production capacity in 2022. Jianfeng Group ranked among the "top 100" in the two lists ". The list of China's top 500 building materials enterprises was officially released in early March. This series of lists was selected by the China Building Materials Enterprise Management Association. Through more than 20 years of comprehensive data research on China's building materials industry, referring to international practices, the rankings are based on the company's annual operating income., Cement products, building ceramics, waterproof materials, aluminum-plastic profiles, coatings, glass, building materials equipment manufacturing and other sub-industries related to building materials. Jianfeng Group ranks 96th among the companies on the list and 27th among the cement manufacturers on the list. On March 16, the awarding ceremony of 2022 China's top 100 cement clinker production capacity list was held in Hangzhou. This series of lists is released by China Cement Network, an authoritative organization in China's cement industry. The ranking is based on the total production capacity (excluding the production capacity of other kiln types and grinding stations) of new dry clinker production lines completed and put into operation by Chinese cement enterprises in China as of December 31, 2022. The data statistics are calculated based on the design production capacity and 310 days of annual operation. Jianfeng Group ranked 53rd with an annual design capacity of 3.627 million tons. (this newspaper reporter)

2023

03-21

Company sends off retired employees

On the morning of February 22, the trade union of the group company held a simple and warm farewell party for retired employees in 2021-2022. More than 50 retired employees gathered together to discuss and exchange with Jiang Xiaomeng and other group leaders.

2023

03-04

On the first day of the new year, group leaders went to the grassroots level.

On January 29, the first day of work after the Spring Festival holiday, the leaders of the group company made a video connection to subordinate enterprises stationed abroad, and separately visited the gold enterprises to learn about the resumption of work and put forward requirements for the implementation of the work plan for the new year.

2023

02-17

Group Companies Commend 2022 Advanced

On the morning of January 18, the group company held the 2022 annual summary commendation meeting to review the work of the previous year, make arrangements for the work in 2023, sign the 2023 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2022 advanced collectives and individuals.

2023

01-29

Jiang Xiaomeng re-elected chairman of the Municipal Federation of Industry and Commerce

On December 24, 2022, the Jinhua Federation of Industry and Commerce (General Chamber of Commerce) held the seventh member representative meeting. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, was re-elected as the chairman of the Municipal Federation of Industry and Commerce at this meeting.

2023

01-12

Peak Pharmaceutical Donates Epidemic Prevention Materials

Since the optimization and adjustment of the new crown infection epidemic management policy, there has been an explosive growth of infected people in the country, and the pressure on the supply of related materials has increased sharply. Before and after New Year's Day, the company has twice organized epidemic prevention materials, through the Jinhua City Charity Federation, Jinhua City Economic and Technological Development Zone Charity Federation targeted donations, a total value of more than 200,000 yuan.

2023

01-12

< 1 2 3 4...61 > 跳转到页